On November 28, 2023 Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that in November the first patient of its Phase Ib clinical trial was successfully treated with OMO-103 – the first direct pan-Myc inhibitor to have completed Phase I clinical trial last year – in combination with the standard of care (SoC) drugs gemcitabine and nab-paclitaxel (Press release, Peptomyc, NOV 28, 2023, View Source [SID1234638010]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This Phase Ib trial includes patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma (PDAC). 4 sites in Spain are currently recruiting: the Hospital Universitari Vall d’Hebrón in Barcelona, the Instituto Catalán de Oncología in Barcelona, the Hospital General Universitario Gregorio Marañón in Madrid and the Hospital Universitario Miguel Servet in Zaragoza. The objective of this study is to evaluate the safety and efficacy of OMO-103 in combination with SoC in first-line metastatic PDAC.

Peptomyc CMO Manuela Niewel said: "We are thrilled to see the first patient successfully treated in this trial and this represents a major milestone for the company and patients we hope to serve" and Peptomyc CEO Laura Soucek added: "I am proud of the work of our team and thankful for the support from clinicians and hospitals who have enabled this important milestone."